Nephroprotection by hypoglycemic agents: Do we have supporting data?

5^th Global Nephrologists Annual Meeting

March 31-April 02, 2016 Valencia, Spain

Jose Luis Gorriz, Javier Nieto, Juan F Navarro-Gonzalez, Pablo Molina, Alberto Martinez-Castelao and Luis M Pallardo

Universidad de Valencia, Spain
Hospital General Universitario de Ciudad Real, Spain
Hospital Universitario N S Candelaria, Spain
Hospital Universitario Bellvitge, Spain
Spanish Society of Nephrology, Spain
Carlos III Researc

Posters & Accepted Abstracts: J Nephrol Ther

Abstract :

Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, renin angiotensin-aldosterone system blockade and multifactorial intervention. However, the renal protection provided by these therapeutic modalities is incomplete. There is a scarcity of studies analyzing the nephroprotective effect of antihyperglycemic drugs beyond their glucose lowering effect and improved glycemic control on the prevention and progression of diabetic nephropathy. This article analyzes the existing data about older and newer drugs as well as the mechanisms associated with hypoglycemic drugs apart from their well-known blood glucose lowering effect in the prevention and progression of diabetic nephropathy. Most of them have been tested in humans but with varying degrees of success. Although experimental data about most of antihyperglycemic drugs has shown a beneficial effect in kidney parameters, there is a lack of clinical trials that clearly prove these beneficial effects. The key question, however, is whether antihyperglycemic drugs are able to improve renal end-points beyond their antihyperglycemic effect. Existing experimental data are post hoc studies from clinical trials and supportive of the potential renal-protective role of some of them, especially in the cases of dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors. Dedicated and adequately powered renal trials with renal outcomes are necessary to assess the nephrotection of antihyperglycemic drugs beyond the control of hyperglycemia.

Biography :

Email: jlgorriz@ono.com, jlgorriz@senefro.org